World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
80
Citations
39584
World Ranking
1596
National Ranking
136

Sergio A. Quezada publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Sergio A. Quezada sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 217 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Sergio A. Quezada D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Sergio A. Quezada sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 80 D-Index — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Sergio A. Quezada is affiliated with University College London in the United Kingdom. Their research spans multiple interconnected fields within biomedical science, emphasizing oncology and immunology.

The main fields of study in Quezada's work include Medicine, Immunology and Microbiology, and Biochemistry, Genetics and Molecular Biology. Within these broader areas, Quezada focuses on several subfields, notably Oncology, Immunology, Molecular Biology, Cancer Research, and Pulmonary and Respiratory Medicine.

The scientist's research addresses various topics related to cancer and immune system interactions. Key topics include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cancer Genomics and Diagnostics, CAR-T Cell Therapy Research, Immune Cell Function and Interaction, Monoclonal and Polyclonal Antibodies Research, and T-cell and B-cell Immunology.

Quezada has contributed to numerous publications, with frequent appearances in several high-profile venues. The most common publication outlets are Cancer Research, Nature, Nature Cancer, bioRxiv (Cold Spring Harbor Laboratory), and Nature Communications.

Frequent collaborators in their work include Charles Swanton, James L. Reading, Teresa Marafioti, Crispin T. Hiley, and Mariam Jamal-Hanjani.

The scientist has published multiple recent research papers, such as:

  • Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition (2021, Cell)
  • Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion (2021, Cell)
  • Embracing cancer complexity: Hallmarks of systemic disease (2024, Cell)
  • Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020, Nature Medicine)
  • Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma (2021, Nature Communications)

Best Publications

  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

    Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

  • Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

    T.A. Chan;M. Yarchoan;E. Jaffee;C. Swanton

  • Tracking the Evolution of Non–Small-Cell Lung Cancer

    Mariam Jamal-Hanjani;Gareth A. Wilson;Nicholas McGranahan;Nicolai Juul Birkbak

  • Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

    Christopher Abbosh;Nicolai J. Birkbak;Nicolai J. Birkbak;Gareth A. Wilson;Gareth A. Wilson;Mariam Jamal-Hanjani

  • Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

    Tyler R. Simpson;Fubin Li;Welby Montalvo-Ortiz;Manuel A. Sepulveda

  • Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

    Nicholas McGranahan;Rachel Rosenthal;Crispin T. Hiley;Crispin T. Hiley;Andrew J. Rowan

  • Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism

    David C. Gondek;Li-Fan Lu;Sergio A. Quezada;Shimon Sakaguchi

  • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

    Karl S. Peggs;Sergio A. Quezada;Cynthia A. Chambers;Alan J. Korman

  • Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

    Santiago Zelenay;Annemarthe G. van der Veen;Jan P. Böttcher;Kathryn J. Snelgrove

  • Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

    Sergio A. Quezada;Tyler R. Simpson;Karl S. Peggs;Taha Merghoub

  • Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

    Samra Turajlic;Samra Turajlic;Kevin Litchfield;Hang Xu;Rachel Rosenthal

  • Neoantigen-directed immune escape in lung cancer evolution

    Rachel Rosenthal;Rachel Rosenthal;Elizabeth Larose Cadieux;Roberto Salgado;Maise Al Bakir

  • CD40/CD154 interactions at the interface of tolerance and immunity

    Sergio A. Quezada;Lamis Z. Jarvinen;Evan F. Lind;Randolph J. Noelle

  • Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

    Kevin Litchfield;Kevin Litchfield;James L. Reading;Clare Puttick;Krupa Thakkar;Krupa Thakkar

  • CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

    Sergio A. Quezada;Karl S. Peggs;Michael A. Curran;James P. Allison

  • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

    Frederick Arce Vargas;Andrew J S Furness;Kevin Litchfield;Kroopa Joshi

  • Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

    Karl S Peggs;Sergio A Quezada;Alan J Korman;James P Allison

  • Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

    Frederick Arce Vargas;Andrew J.S. Furness;Andrew J.S. Furness;Isabelle Solomon;Kroopa Joshi;Kroopa Joshi

  • A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

    Brian Philip;Evangelia Kokalaki;Leila Mekkaoui;Simon Thomas

  • Translational Implications of Tumor Heterogeneity

    Mariam Jamal-Hanjani;Sergio A. Quezada;James Larkin;Charles Swanton

  • Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

    Adel Samson;Karen J. Scott;David Taggart;Emma J. West

  • Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

    Amalie Kai Bentzen;Andrea Marion Marquard;Rikke Lyngaa;Sunil Kumar Saini

Frequent Co-Authors

Charles Swanton
Charles Swanton The Francis Crick Institute
Karl S. Peggs
Karl S. Peggs University College London
Javier Herrero
Javier Herrero University College London
James P. Allison
James P. Allison The University of Texas MD Anderson Cancer Center
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Allan Hackshaw
Allan Hackshaw University College London
Randolph J. Noelle
Randolph J. Noelle Dartmouth College
Peter Van Loo
Peter Van Loo The Francis Crick Institute
Zoltan Szallasi
Zoltan Szallasi Boston Children's Hospital
Caroline Dive
Caroline Dive University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens various doors, especially when combined with healthcare and nursing careers. Many students interested in immunology pursue advanced nursing degrees to work in specialized medical fields. For those aiming to boost their nursing credentials quickly, an accelerated nurse practitioner program offers a fast-track to becoming a licensed nurse practitioner.

Transitioning within nursing roles is also common. For example, registered nurses with a Family Nurse Practitioner (FNP) certification often seek to broaden their clinical expertise by moving into acute care. Learning how to transition from FNP to acute care NP can enhance career opportunities, especially in hospital settings where immunology knowledge is valuable.

Additionally, individuals without a nursing background can enter the field through online options like online BSN programs for non nurses. These programs equip students with essential nursing skills and knowledge, forming a solid foundation for specialized practice areas including immunology.

Understanding the financial benefits of these career pathways is key. For instance, exploring how much do DNP nurses make by state helps prospective students gauge potential returns on their educational investment and plan their careers accordingly.

Best Scientists Citing Sergio A. Quezada

Trending Scientists

Recently Published Articles